Eli Lilly widens market cap gap with Novo Nordisk in obesity treatment competition
NVO Novo Nordisk ADR
$40.70 -1.64%
View chart & analysis → 
- 1Eli Lilly's market capitalization is nearly 9 times that of Novo Nordisk.
- 2Lilly currently leads the market with a 63% share in the US market.
- 3Novo Nordisk received approval for Ozempic in 2017.
So what's the key point?
Eli Lilly is leading the US obesity treatment market with a 63% share. This means the company's value has become much larger than Novo Nordisk's and it is driving the market.
Source The Motley Fool +7 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.